Researchers performed preclinical studies to elucidate Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3)’s role in immune checkpoint inhibitors-resistant mouse mesothelioma.
[Clinical Cancer Research]
Home Newsletters Immune Regulation News Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
